Cyclerion Therapeutics Inc (OQ:CYCN)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 301 Binney St
CAMBRIDGE MA 02142-1030
Tel: N/A
Website: N/A
Key People
Business Overview
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing treatments for serious and orphan diseases. The Company develops guanylate cyclase (sGC) stimulators. The Company's portfolio includes five sGC stimulator programs: olinciguat, praliciguat, IW-6463 and two organ-targeted programs. Olinciguat is an oral, once-daily vascular sGC stimulator for patients suffering from sickle cell disease. Olinciguat is in Phase II trial. Praliciguat is an oral, once-daily systemic sGC stimulator for heart failure with preserved ejection fraction (HFpEF) and for diabetic nephropathy. Praliciguat is in two separate Phase II trials. IW-6463 is a central nervous system-penetrant oral sGC stimulator. IW-6463 is in a Phase I and is designed to treat serious and orphan neurodegenerative diseases. Its two organ-targeted programs are designed to address serious and orphan diseases of the liver and lung.
Financial Overview
For the fiscal year ended 31 December 2018, Cyclerion Therapeutics Inc revenues was not reported. Net loss increased 23% to $115.3M. Higher net loss reflects General & Administrative - Balancing increase of 90% to $22.2M (expense), Research & Development - Balancing value increase of 11% to $80.6M (expense), Stock-based Compensation in SGA increase of 56% to $5.3M (expense).
Employees: 140 as of Feb 28, 2019
Reporting Currency: U.S. Dollars
Enterprise value: N/A
Annual revenue (TTM): $0.00M as of Dec 31, 2018
EBITDA (TTM): -$113.72M as of Dec 31, 2018
Net annual income (TTM): -$115.25M as of Dec 31, 2018
Free cash flow (TTM): -$100.94M as of Dec 31, 2018
Net Debt Last Fiscal Year: $0.00M as of Dec 31, 2018
Shares outstanding: 27,304,462 as of Apr 2, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization